A group of 49 white South Africans departed their homeland Sunday for the United States on a private charter plane having ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

As Stat reports, the federal judge's ruling means patients will lose access to less-expensive versions of Eli Lilly's weight loss drug, as well as diabetes treatment Mounjaro, from compounding ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Eli Lilly rose Friday after topping Wall Street's first-quarter expectations. Eli Lilly stock bounced back after tumbling Thursday after CVS' Caremark selected Novo Nordisk's Wegovy as its preferred ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

It promotes well-known treatments such as Mounjaro, Trulicity, Zepbound, Verzenio, and Jaypirca. Eli Lilly and Company (NYSE:LLY) surpassed expectations in 2024, exceeding initial sales guidance ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan ... the sort of shortages that plagued its rollout of Mounjaro and Zepbound, Orforglipron complements Mounjaro, which had $11.5 billion in sales ...

Eli Lilly sued Willow Health Services Inc., based ... which treats diabetes, and Zepbound, which treats obesity. Compound medicine providers were allowed to make and distribute copycat versions ...